.'.' Data from more than 2,000 adult patients were used for the development of this IPI, which is based on pretreatment clinical characteristics only. Eligibility for the study was specified categories of the Working Formulation, the Kiel classification, and the Rappaport classification; they were summarized as "intermediate grade" according to the Working Formulation (WF).' All patients were treated with a combination chemotherapy regimen containing doxorubicin as part of phase I1 or phase 111 trials between 1982 and 1987. The IPI Project Group expressed the wish to use their IPI in the design of future trials and in the choice of therapy for individual patients with aggressive NHL.
ECENTLY, THE International Non-Hodgkin's Lymphoma Prognostic Factors Project developed an International Prognostic Index (IPI) for patients with aggressive non-Hodgkin's lymphoma (NHL).'.' Data from more than 2,000 adult patients were used for the development of this IPI, which is based on pretreatment clinical characteristics only. Eligibility for the study was specified categories of the Working Formulation, the Kiel classification, and the Rappaport classification; they were summarized as "intermediate grade" according to the Working Formulation (WF).' All patients were treated with a combination chemotherapy regimen containing doxorubicin as part of phase I1 or phase 111 trials between 1982 and 1987. The IPI Project Group expressed the wish to use their IPI in the design of future trials and in the choice of therapy for individual patients with aggressive NHL.
We had the opportunity to investigate whether the prognostic value of this IPI for response to therapy, survival, and relapse could be confirmed on a different and unselected cohort of WF intermediate grade patients. Our cohort was not restricted by a series of entry criteria, which usually hold for clinical trials, but was population-based in a certain geographic region. Moreover, we investigated whether the IPI also had prognostic value for NHL patients with a lowgrade and a high-grade malignancy according to the WF. Based on a single institution series of 125 patients, the IPI proved to be a useful prognostic tool for low-grade NHL patients, as ~e l I .~. ' These two aspects concerning the IPI, confirmation and extension, were studied on a population-based database of turned out to be of prognostic value for response rate and survival in our unselected cohort of 744 patients, as well. In each of the three WF classes separately, the four IPI classes showed going from low to high substantially decreasing response rates and survival percentages. For 
MATERIALS AND METHODS

Patients and treatment.
Included in the database were all patients (n = 1,168) newly diagnosed as and treated for NHL in the period 1981 to 1989 in one of the hospitals in the region of the CCCW, which has 1.6 million inhabitants. A first description of the database has been given by Otter et aLh To be included, the patient's diagnosis had to be confirmed by a panel of pathologists and the patient had to live inside the region of the CCCW (identified by postal code). Excluded were patients with primary cutaneous T-cell lymphoma, acute lymphoblastic and classical chronic lymphocytic leukemia, multiple myeloma, plasmacytoma, patients with only cytologic diagnosis, and patients with only a postmortem diagnosis. Anamnestic, diagnostic, and therapeutic data were retrieved from the patient's hospital files. The follow-up for the database is annually updated for the patients alive. Treatment was left to the discretion of the local physician. The Appendix lists all participating hospitals. were excluded because they could move to stage IV and, consequently, to an IPI one class higher as a result of a complete staging. Localizations in the tonsils, Waldeyer's ring, and spleen were classified as nodal sites.
The following outcome parameters were studied and broken down according to the WF related to the IPI classes: complete response to therapy, overall survival from diagnosis, and for the complete responders, the relapse-free survival from end of therapy.
Survival curves were calculated according to the Kaplan and Meier method; survival analysis was performed using the log-rank test.
RESULTS
The characteristics of the 744 patients of the CCCW database, reported in this report, as well as the patients used by the IPI Project Group are given in Table 1 The resulting distribution over the IPI classes can be found in Table 2 . For the intermediate grade, it was comparable to the distribution in the IPI Project Group cohort. The distribution was rather similar for the high-grade NHL and shifted to the lowhntermediate for the low-grade NHL.
Moreover, Table 2 gives the outcome results for complete response rates, relapse-free survival, and overall survival for each of the four IPI classes. The overall survival curves for the CCCW database (Fig 1) show that for all three WF categories the four IPI classes have a strong prognostic value.
This conclusion is further supported by the complete response rates given in Table 2 . The 5-year percentages for relapse-free survival, also given in Table 2 , are in line with this conclusion for the intermediate grade, but not well evaluable for the low and high grades.
Comparison of our WF category intermediate grade with the results of the IPI Project Group showed some remarkable differences. As documented in Table 2 , complete response rates, relapse-free survival at 5 years, and overall survival at 5 years are substantially higher for the IPI Project Group patients.
DISCUSSION
The members of the IPI Project Group developed a prognostic index ( P I ) for patients with aggressive non-Hodgkin's lymphoma. They focused on the prognostic value of pretreatment clinical characteristics. In total, 3,276 adult patients, originally included in several clinical trials, entered their Table 2. HERMANS ET AL study; for 2,031 patients (62%), information on the clinical characteristics was complete. Development of the index was done on a training sample of 1,385 patients and validation on the remaining 646 patients.
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Our intention was to study whether the prognostic value of the IPI could be confirmed on a different patient cohort and to see whether the usefulness of the IPI could be extended to NHL patients of other malignancy grades. The differences between the IPI Project Group's NHL population and ours have to be emphasized. Their population was intermediate grade W, whereas ours covered the three distinct grades low, intermediate, and high. Their population had to fulfill the inclusion criteria of phase I1 and phase 111 clinical trials. Our population included all patients diagnosed as and treated for NHL in a given region, which is especially reflected by a markedly older cohort. Their population had a protocolized combination chemotherapy treatment, all regimens containing doxorubicin. In our study cohort, treatment was left to the discretion of the physician. Thus, compared with the IPI Project Group cohort our intermediate grade study population is more heterogenous, but represents the average presenting population of NHL patients. This probably explains why the outcome in our intermediate grade is worse compared with the IPI Project Group outcome ( Table  2) . However, the prognostic value of the IPI is confirmed in our series of intermediate grade patients. Moreover, the prognostic value of the IPI turned out to hold also for the low-grade and high-grade NHL in our series (see Fig l) , so extension to these categories is justified for the patients in our database.
L6pez-Guillermo et a14 studied the IPI for a single institution series of 125 low-grade lymphomas. They found good prognostic power for the IPI in their series, also when restricted to 107 follicular lymphomas. They reported a similar tendency for the L/I and VH risk classes and decided to classify the patients in only three index classes (low, intermediate, and high). We did not find a similar tendency.
Contrary, AvilCs' reported recently for a single institution series of 238 low-grade NHL patients no prognostic value for the IPI. For his series with a short median follow-up (treatment period 1986 to 1991) and uniformly treated with combined chemotherapy followed by radiotherapy to sites of nodal involvement, complete response rates, as well as 7-year survival percentages, were very similar.
We conclude that the International Prognostic Index, divided into four categories, is applicable to unselected NHL patients for all three malignancy grades of the WF. 
